Canadian panel recommends AstraZeneca vaccine pause for under 55
Mar 30 2021
While no VIPIT cases have been identified domestically, Health Canada will require the manufacturers conduct a "detailed assessment of the benefits and risks of the vaccine by age and sex in the Canadian context".
This latest recommendation follows reports in Europe that about three dozen patients developed blood clots following immunization with the AstraZeneca vaccine, majority younger women.
Health Canada has stated that the AstraZeneca COVID-19 vaccine continues to be safe and effective at protecting Canadians against COVID-19 and encourages people to get immunized with any of the COVID-19 vaccines that are authorized in Canada.
NACI has recommended that Canada and the provinces should hold off on giving the AstraZeneca-Oxford COVID-19 vaccine to Canadians under 55 owing to some safety concerns coming out of Europe.
The vaccine is used widely in Britain, across the European continent and in other countries, but its rollout was troubled by inconsistent study reports about its effectiveness, and then more recently a scare about clots that had some countries temporarily pausing inoculations.
The health agency said the report follows "very rare adverse" events in Europe.
Canada, like several other countries, suspended the use of the AstraZeneca vaccine entirely earlier in March.
Morrison said people should also feel assured that public health officials are taking every development extremely seriously. Typically, the symptoms would show up between four and 20 days post-injection.
Mexico expects to receive 2.7 million doses from the USA where the AstraZeneca jab has not yet been approved.
Germany's Robert Koch Institute for infectious diseases (RKI) reported 9,549 new COVID-19 cases in the previous 24 hours on Tuesday.
"This information will support the ongoing evaluation of these rare blood clotting events, and allow Health Canada to determine if there are specific groups of people who may be at higher risk", the information from Health Canada reads.
It is a recommendation and it is up to each of Canada's provinces to decide to follow it or not.
"A single mRNA batch of the current scale is sufficient to produce around eight million vaccine doses", explains BioNTech. "Currently, 400 BioNTech employees work in Marburg, 200 of them in 24/7 shifts in order to maximize the production's output. Health Canada will be reviewing this evidence when available".
"As you know, AstraZeneca has been under examination by a number of jurisdictions for its connection to potentially adverse effects", said Hajdu on Monday.
"It's important for everyone when it's their turn to get a vaccine", said Elliott.
Canada has received 500,000 doses so far and is expecting another 1.5-million before the end of May.